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DOXORUBICIN AND CISPLATIN (M-VAC) THERAPY 
Hisami F四 UDA，Kenji MITSUMORI， Shingo MINAGAWA， Teruaki KUMAZAWA， 
Kazuteru TADACHI， Masahiro IrNUMA， Shigeru SATOH， Kazunari SATOH， 
Tomonori HABUCHI and Tetsuro KATO 
7ちeDψartment 01 Urology， Ak山 UniversiりSchool01 Medicine 
We report two cases of metastatic urothelial cancer treated with high-dose-intensity (HD) 
methotrexate vinblastine， doxorubicin and cisplatin (MV AC). After HD-MV AC， the size of primary 
and lymph node tumors decreased by 57-67% as compared with the standard M-V AC therapy. By 
shortening the dose interval， HD・.MVACmay increase the anti-tumor effect without increasing side 
effects. 
(Hinyokika Kiyo 51: 113-116， 2005) 







intensity-MV AC (HD-MV AC)療法は，従来の
MVAC療法の15，22日目の methotrexate(MTX) 
とvinblastine(VBL)の投与を省略し， 4-10日目の
計画的な G-CSF投与により Iコースの期間を 2週間




Day 1 MTX 30mg/m2 MTX 30mg/m2 
Day 2 VBL 3 mg/m2 VBL 3 mg/m2 
ADR 30mg/m2 ADR 30mg/m2 
CDDP 70 mg/m2 CDDP 70 mg/m2 
Day 十10 G心SF240μg/m2 
Day 15・22 な し MTX 30mg/m2 
VBL 3 mg/m2 
G-CSF 必与中10
4


















TCC， G2-3， T4NOMlと診断， 8月2日から HD-
MVAC療法を開始した.
G心SFは原法と異なり頼粒球数をみながら投与し
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Fig. 1. ChestXP and computed tomography (CT) images before (A-l， A-2) and after (B-l， B-2) chem-
otherapy. 
Fig. 2. Compute~tomograp~y (CT) images of the pelvis before (A) and after (B) chemotherapy in 



















Fig. 3. Computed tomography (CT) images before (A-1， A-2) and after (B-1， B・2)chemotherapy in 
case 2. The maximal diameters of ureter.al tumor and para-aortic Iymph node metastasis (A・2
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